Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Aberdeen Health Technology Assessment Group:

  • Royle P, Cummins E, Henderson R et al. Ranibizumab for the treatment of diabetic macular oedema: a single technology appraisal. Aberdeen HTA Group 2011

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document. Organisations listed in 1 were also invited to make written submissions. Organisations listed in 2 and 3 had the opportunity to give their expert views. Organisations listed in 1 and 2 also have the opportunity to appeal against the final appraisal determination.

1 Manufacturer or sponsor:

  • Novartis

2 Professional or specialist and patient or carer groups:

  • Diabetes UK

  • Macular Disease Society

  • Royal College of Nursing

  • Royal College of Ophthalmologists

  • Royal College of Physicians

  • Royal National Institute of Blind People (RNIB)

3 Other consultees:

  • Department of Health

  • Bridgend LHB

  • Welsh Assembly Government

4 Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • NHS Quality Improvement Scotland

  • Roche Products

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on ranibizumab by attending the initial Committee discussion for NICE technology appraisal 237 and providing written evidence to the Committee. They were also invited to comment on the appraisal consultation document.

  • Claire Bailey, nominated by the Royal National Institute of Blind People – clinical specialist

  • Professor Yit Yang, nominated by the Royal College of Ophthalmologists – clinical specialist

  • Jennifer Nosek, nominated by the Royal College of Nursing – clinical specialist

  • Barbara McLaughlan, nominated by Royal National Institute of Blind People – patient expert

  • Michael Stroud, nominated by Royal National Institute of Blind People – patient expert

D Representatives from the following manufacturer or sponsor attended Committee Meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Novartis

  • National Institute for Health and Care Excellence (NICE)